36TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2025 Today, Indena’s ambition is to extend its expertise to ADCs, which represent a significant advancement in targeted therapy, holding immense promise for the pharmaceutical industry. These engineered molecules combine the specificity of monoclonal antibodies with the potent cytotoxicity of chemotherapeutic drugs, offering a more precise and potentially less toxic approach. One of the most important factors for the quality of the CDMO services delivered by Indena is people. It means the human and professional resources of the whole teams working on CDMO activities, where lifelong professional experiences are fused with the enthusiasm and fresh skills of many young scientists. Because at Indena it is well-known that highly qualified, motivated and trained technical staff, supported by a corporate culture, strongly oriented toward quality and rigorous HSE policies, is essential to ensure that operations run safely, seamlessly and efficiently. of the conditions that use HPAPIs include: cancers, auto-immune disorders, infectious diseases and rare diseases. In addition, Indena is at the forefront in addressing the latest market challenges, as its capability in HPAPIs production comes from the experience done more than 30 years ago with the first oncological blockbuster drug, Paclitaxel. The production of Paclitaxel involved some challenges: the development of a sustainable supply chain for the ingredient; the development of a method of isolation under high-containment conditions; and the analytical methodology of control according to stringent pharmaceutical protocols in terms of purity and stability. The solution devised by Indena for Paclitaxel was an extraordinary result and created a unique expertise of the company – from its experience of working with nature, Indena has learned to manage complex molecules of any type, from both the analytical and the production perspectives. INDENA
RkJQdWJsaXNoZXIy MjY2OTA4MA==